Related Articles
Is it reasonable to consider second-line chemotherapy in patients with hormone-refractory prostate cancer?
Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: A phase II study
Low-dose docetaxel, estramustine and prednisolone combination chemotherapy for castration-resistant prostate cancer
Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer
Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer